These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The pharmacokinetics and bioavailability of nomifensine maleate in healthy men. Lassman HB; Puri SK; Ho I; Sabo R; Rosenkilde HC J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):26-32. PubMed ID: 6715299 [TBL] [Abstract][Full Text] [Related]
6. Kinetics and metabolism of nomifensine. Heptner W; Hornke I; Uihlein M J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):21-5. PubMed ID: 6370971 [TBL] [Abstract][Full Text] [Related]
7. Metabolism of nomifensine in man and animal species. Heptner W; Hornke I; Cavagna F; Fehlhaber HW; Rupp W; Neubauer HP Arzneimittelforschung; 1978; 28(1):58-64. PubMed ID: 415744 [No Abstract] [Full Text] [Related]
8. The pharmacokinetics of nomifensine. Comparison of pharmacokinetics and pharmacodynamics using computer pharmaco-EEG. Saletu B; Grünberger J; Linzmayer L; Taeuber K Int Pharmacopsychiatry; 1982; 17 Suppl 1():43-72. PubMed ID: 7129805 [TBL] [Abstract][Full Text] [Related]
9. The comparative disposition of nomifensine (Merital) in the pregnant and non-pregnant rat. Ings RM Arch Int Pharmacodyn Ther; 1979 Dec; 242(2):180-95. PubMed ID: 543752 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of nomifensine in impaired renal function. Ringoir S; Lameire N; Munche M; Heptner W; Taeuber K Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):129S-134S. PubMed ID: 334214 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Han KS; Kim YG; Yoo JK; Lee JW; Lee MG Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211 [TBL] [Abstract][Full Text] [Related]
12. Determination of nomifensine by a sensitive radioimmunoassay. Heptner W; Badian MJ; Baudner S; Christ OE; Fraser HM; Rupp W; Weimer KE; Wissmann H Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):123S-127S. PubMed ID: 911648 [TBL] [Abstract][Full Text] [Related]
13. Kinetic interaction of nomifensine with a 1, 5-benzodiazepine (clobazam). Rupp W; Heptner W; Uihlein M; Bender R; Taeuber K Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):143S-146S. PubMed ID: 334216 [TBL] [Abstract][Full Text] [Related]
14. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs. Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105. Mukai H; Sugimoto T; Ago M; Morino A Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039 [TBL] [Abstract][Full Text] [Related]
16. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys. Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Usui T; Watanabe T; Higuchi S Drug Metab Dispos; 1995 Nov; 23(11):1214-9. PubMed ID: 8591721 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504 [TBL] [Abstract][Full Text] [Related]
19. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Setnikar I; Rovati LC Arzneimittelforschung; 2001 Sep; 51(9):699-725. PubMed ID: 11642003 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]